NASDAQ$AIXC
AIxCrypto Holdings Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Ritter Pharmaceuticals reported financial results for Q4 2019, showing a net loss decrease due to winding down development efforts as the Liberatus clinical trial entered its finalization stage, and announced a definitive merger agreement with Qualigen, Inc.
Ritter Pharmaceuticals reported a net loss of $0.4 million for the fourth quarter ended December 31, 2019, compared to a net loss of $6.6 million for the same period in 2018. The company's cash and cash equivalents were approximately $1.7 million as of December 31, 2019. A definitive merger agreement with Qualigen, Inc. was announced in January 2020.
- Net loss for Q4 2019 was $0.4 million, compared to $6.6 million for Q4 2018.
- Net loss per share for Q4 2019 was $0.05, compared to $1.73 for Q4 2018.
- Cash and cash equivalents were approximately $1.7 million as of December 31, 2019.
- A definitive merger agreement with Qualigen, Inc. was announced in January 2020.
Headline financials
Revenue & EPS history
Qualigen · Revenue · Quarterly
-$2.71M
Revenue by segment
Qualigen · $700K total across 1 segment · Q1 2022
- Product Sales$700K-50.0%100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-1.6%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-8.3%
Avg return
30 days after
43%
16 / 37 earnings
Positive
+18.8%
Q3 2016
Best reaction
-22.8%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +10.4% | -3.7% | -13.2% | |
| Q2 2025 | +6.8% | +7.1% | +19.0% | |
| Q1 2025 | +2.0% | -7.0% | -37.4% | |
| Q3 2024 | -12.6% | -6.3% | -6.1% | |
| Q2 2024 | -1.7% | +8.5% | -17.5% | |
| Q1 2024 | +5.7% | +68.7% | +41.6% | |
| Q4 2023 | +1.0% | -15.9% | -29.1% | |
| Q3 2023 | +4.5% | +2.4% | -14.7% | |
| Q2 2023 | +1.0% | +2.9% | -6.4% | |
| Q1 2023 | -5.9% | -3.8% | -5.9% | |
| Q4 2022 | +0.9% | +12.7% | +0.8% | |
| Q3 2022 | -4.5% | -3.2% | -35.5% | |
| Q2 2022 | -0.2% | -3.5% | -23.1% | |
| Q1 2022 | +5.4% | +0.0% | +20.8% | |
| Q4 2021 | -3.2% | -5.5% | -15.3% | |
| Q3 2021 | +0.9% | -6.1% | -9.0% | |
| Q2 2021 | -22.8% | -29.3% | -12.0% | |
| Q1 2021 | +17.6% | +20.3% | +46.4% | |
| Q4 2020 | +5.8% | +1.2% | -17.3% | |
| Q4 2019 | -14.0% | -13.5% | +6.9% | |
| Q3 2019 | -16.6% | -25.3% | -31.5% | |
| Q2 2019 | -1.4% | +4.1% | -64.5% | |
| Q1 2019 | -2.8% | -9.6% | -5.1% | |
| Q4 2018 | +10.0% | +9.4% | -10.7% | |
| Q3 2018 | -12.0% | -12.2% | -17.3% | |
| Q2 2018 | -2.4% | -5.9% | -18.5% | |
| Q1 2018 | +1.1% | +13.1% | +7.4% | |
| Q4 2017 | -4.9% | +2.7% | +9.3% | |
| Q3 2017 | -7.2% | -11.1% | -15.3% | |
| Q2 2017 | -4.4% | -6.7% | -2.5% | |
| Q1 2017 | -1.7% | -4.7% | -8.4% | |
| Q4 2016 | -11.4% | +6.6% | -44.6% | |
| Q3 2016 | +18.8% | +25.0% | +23.1% | |
| Q2 2016 | +1.5% | -2.3% | +4.6% | |
| Q1 2016 | -2.8% | — | — | |
| Q3 2015 | -4.7% | — | — | |
| Q2 2015 | -13.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro